202 related articles for article (PubMed ID: 33649846)
1. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Suetsugu T; Mori R; Futamura M; Fukada M; Tanaka H; Yasufuku I; Sato Y; Iwata Y; Imai T; Imai H; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yoshida K
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649846
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells.
Mori R; Yoshida K; Futamura M; Suetsugu T; Shizu K; Tanahashi T; Tanaka Y; Matsuhashi N; Yamaguchi K
Gastric Cancer; 2019 May; 22(3):497-505. PubMed ID: 30276573
[TBL] [Abstract][Full Text] [Related]
3. The mechanism underlying resistance to 5-fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells.
Mori R; Ukai J; Tokumaru Y; Niwa Y; Futamura M
Oncol Lett; 2022 Sep; 24(3):311. PubMed ID: 35949616
[TBL] [Abstract][Full Text] [Related]
4. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.
Ghosh S; Singh R; Vanwinkle ZM; Guo H; Vemula PK; Goel A; Haribabu B; Jala VR
Theranostics; 2022; 12(12):5574-5595. PubMed ID: 35910798
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
6. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
[TBL] [Abstract][Full Text] [Related]
7. 5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine.
Mori R; Futamura M; Tanahashi T; Tanaka Y; Matsuhashi N; Yamaguchi K; Yoshida K
Oncol Lett; 2017 Sep; 14(3):3162-3168. PubMed ID: 28927061
[TBL] [Abstract][Full Text] [Related]
8. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.
de Bruin M; van Capel T; Van der Born K; Kruyt FA; Fukushima M; Hoekman K; Pinedo HM; Peters GJ
Br J Cancer; 2003 Mar; 88(6):957-64. PubMed ID: 12644837
[TBL] [Abstract][Full Text] [Related]
9. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
Temmink OH; de Bruin M; Turksma AW; Cricca S; Laan AC; Peters GJ
Int J Biochem Cell Biol; 2007; 39(3):565-75. PubMed ID: 17098463
[TBL] [Abstract][Full Text] [Related]
10. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
11. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
12. Novel quinazolinone MJ‑33 induces AKT/mTOR‑mediated autophagy‑associated apoptosis in 5FU‑resistant colorectal cancer cells.
Ha HA; Chiang JH; Tsai FJ; Bau DT; Juan YN; Lo YH; Hour MJ; Yang JS
Oncol Rep; 2021 Feb; 45(2):680-692. PubMed ID: 33416156
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
14. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
[TBL] [Abstract][Full Text] [Related]
15. The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
Matsushita S; Ikeda R; Nishizawa Y; Che XF; Furukawa T; Miyadera K; Tabata S; Ushiyama M; Tajitsu Y; Yamamoto M; Takeda Y; Minami K; Mataki H; Kanzaki T; Yamada K; Kanekura T; Akiyama S
Int J Oncol; 2010 May; 36(5):1193-200. PubMed ID: 20372793
[TBL] [Abstract][Full Text] [Related]
16. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells.
Temmink OH; Comijn EM; Fukushima M; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1491-4. PubMed ID: 15571283
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine.
Zhang ZG; Malmberg M; Yin MB; Slocum HK; Rustum YM
Biochem Pharmacol; 1993 Mar; 45(5):1157-64. PubMed ID: 8461045
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
Gmeiner WH; Reinhold WC; Pommier Y
Mol Cancer Ther; 2010 Dec; 9(12):3105-14. PubMed ID: 21159603
[TBL] [Abstract][Full Text] [Related]
19. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C; Mitrovski B
Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
